Video

Healthcare Team Members Involved in Treating Myeloproliferative Neoplasms

Author(s):

Ruben Mesa, M.D.,Rami S. Komrokji, M.D.

Comprehensive insight on the various healthcare team members a hematologist-oncologist may work with to optimize care of myeloproliferative neoplasms.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Image of Crispino
Picture of Joy Anderson
Image of doctor.
Dr. Richard “Rick" Winneker
Image of man with grey hair.
Image of woman with blonde hair.
Image of man with grey hair.
Image of man with grey hair.
Image of bald man in suit.
Related Content
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis: © stock.adobe.com
April 19th 2025

Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis

Alex Biese
Optimal dosing of Jakafi was associated with improved efficacy and manageable safety in patients with myelofibrosis, according to the ROMEI clinical trial.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Illustration of blood cells.
March 16th 2025

Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset

Spencer Feldman
Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Illustration of red blood cells.
January 20th 2025

Subcutaneous Dacogen Elicits Responses Among Some With Myelofibrosis

Alex Biese
Ten days of subcutaneous Dacogen resulted in responses among a third of patients with myelofibrosis.
Illustration of red blood cells.
January 10th 2025

P1101 Treatment Meets Phase 3 Primary End Point in Essential Thrombocythemia

Ryan Scott
P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET.